We used a computer-generated sequence to randomly assign patients ( 1:1 ) to receive rituximab ( 375 mg/m ( 2 ) ) or placebo once weekly for 4 weeks , with age , institution , treatment history , and the intervals between the previous three relapses as adjustment factors .